Clinical Trial Update: Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 dose-finding study evaluating the combination of ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma; results have bee…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Imbruvica (ibrutinib) (ibrutinib)
• Revlimid (lenalidomide) (lenalidomide)
• Rituxan (rituximab) (rituximab)

Snippet

Sponsor: Hackensack Meridian Health | Conditions: Mantle Cell Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-01-26